Publications

📝Jovana Dedeić, Jelena Ivetić, Srđan Milićević, Katarina Vidojević, Marija Delić

XT-REM: A Two-Component Model for Meta-Analysis of Extreme Event Proportions

✍️In preparation.

📝Zahra Alirezaei, Martin Horvat, Marija Delić, Katja Strašek, Daniel Huff, Robert Jeraj

Quantifying Risk Assessment in Immune Checkpoint Inhibitors Treatment of Malignant Melanoma 

✍️In preparation. 

📄Zahra Alirezaei, Martin Horvat, Marija Delić, Katja Strašek, Daniel Huff, Robert Jeraj

PET Imaging Biomarker–Driven Risk Modeling and Surrogacy Assessment of Immune-Related Adverse Events in Melanoma Immunotherapy

📌The abstract has been accepted at the European Molecular Imaging Meeting 2026.

🖼️View the conference poster here.

📄Jovana Dedeić, Jelena Ivetić, Srđan Milićević, Katarina Vidojević, Marija Delić

XT-REM: Dvokomponentni model za robusnu meta-analizu proporcija ekstremnih događaja

📌The abstract has been accepted at the XV Symposium "Mathematics and Applications”.

📄Katarina Vidojević, Jovana Dedeić, Srđan Milićević, Jelena Ivetić, Marija Delić

META-ANALYSIS OF IMMUNOTHERAPY OUTCOMES IN METASTATIC MELANOMA

📌Review paper published in Conference Proceedings META 2025.

🔗https://doi.org/10.24867/META.2025.19

📝Jelena Ivetić, Jovana Dedeić, Srđan Milićević, Katarina Vidojević, Marija Delić

Comparative Meta-Analysis of Survival, Risk, and Treatment Efficacy in Immunotherapy for Metastatic Melanoma Using Random-, Fixed-, and Mixed-Effects Models

📌Published in Journal of Clinical Medicine 2025, Volume 14, Issue 14, 5017.

🔗https://doi.org/10.3390/jcm14145017

📄Zahra Alirezaei,  Martin Horvat, Marija Delić, Katja Strašek, Daniel Huff, Robert Jeraj

Quantifying Risk Assessment in Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma

📌Slovenian Physics Conference in Kranj.

🖼️View the conference poster here.

💻Software for Visualisation of Patient Risk-Benefit Space
An open-source software package for visualising patient risk-benefit space.
🔗The code, documentation, and example are available on https://github.com/katarinavidojevic/risk-benefit-visualization.

📄Srđan Milićević, Jovana Dedeić, Katarina Vidojević, Jelena Ivetić, Marija Delić

Model-based meta-analysis of adverse events in metastatic melanoma immunotherapy: The importance of quantifying heterogeneity

📌The abstract has been accepted at the RAD 2025 Conference.

📘 Abstract available in the Book of Abstracts of the RAD 2025 Conference, page 28. 

📄Marija Delić, Martin Horvat, Katja Strašek, Daniel Huff, Robert Jeraj

Quantifying risks in immunotherapy using bayesian modelling of quantitative imaging biomarkers

📌The abstract has been accepted at the RAD 2025 Conference.

📘 Abstract available in the Book of Abstracts of the RAD 2025 Conference, page 101. 

📄Marija Delić, Srđan Milićević, Katarina Vidojević, Jovana Dedeić, Jelena Ivetić

Meta-analysis of risks and benefits in immunotherapy treatment of metastatic melanoma  

📌The abstract has been accepted at the RAP 2025 Conference.

📘 Abstract available in the Book of Abstracts of the RAP 2025 Conference, page 195. 

🖼️View the conference poster here.

📄 Srđan Milićević, Buda Bajić, Katarina Vidojević, Marija Delić

Classification of melanoma patients treated by immunotherapy

📌 In Proceedings of the 30th International Symposium on Analytical and Environmental Problems (2024).

🔗 Conference Website